Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma

Clinical Trial ID NCT00329719

Rank	Title	Journal	Year	PubWeight™‹?›
1	Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?	Nat Rev Clin Oncol	2012	1.65
2	Targeting protein kinases in central nervous system disorders.	Nat Rev Drug Discov	2009	1.45
3	Pathway inhibition: emerging molecular targets for treating glioblastoma.	Neuro Oncol	2011	1.38
4	Therapeutic targeting of autophagy in disease: biology and pharmacology.	Pharmacol Rev	2013	1.25
5	Experimental approaches for the treatment of malignant gliomas.	Pharmacol Ther	2010	1.23
6	Targeting Ras-RAF-ERK and its interactive pathways as a novel therapy for malignant gliomas.	Curr Cancer Drug Targets	2010	1.07
7	Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies.	Clin Cancer Res	2011	0.95
8	Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.	Expert Rev Neurother	2009	0.95
9	Unique biology of gliomas: challenges and opportunities.	Trends Neurosci	2012	0.87
10	The mTOR signaling pathway as a treatment target for intracranial neoplasms.	Neuro Oncol	2014	0.84
11	Prognostic and predictive biomarkers in adult and pediatric gliomas: toward personalized treatment.	Front Oncol	2014	0.79
12	Targeted therapy in the treatment of malignant gliomas.	Onco Targets Ther	2009	0.78